{"id":"W2773179393","doi":"10.3899/jrheum.170429","title":"Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)","year":2017,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Eli Lilly and Company","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Erythema; Adverse effect; Placebo; Internal medicine; Rheumatology; Adalimumab; Psoriasis; Population; Arthritis; Surgery; Dermatology; Secukinumab; Rheumatoid arthritis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003127808,0.000166153,0.0009376417,0.00009987526,0.0002140757,0.00001120662,0.0001659389,0.0000565813,0.0000161348],"category_scores_gemma":[0.0004390288,0.00009821045,0.00004791031,0.00005633876,0.0002663097,0.0001194497,0.00008652055,0.000259046,0.000001942552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004337553,"about_ca_system_score_gemma":0.00007385606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001502531,"about_ca_topic_score_gemma":0.001168277,"domain_scores_codex":[0.998453,0.0001516234,0.0007732717,0.0001513292,0.0002686294,0.0002022084],"domain_scores_gemma":[0.9978232,0.0003682599,0.001137808,0.0003997764,0.000188452,0.00008251517],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1946742,0.008513375,0.6408527,0.00001928387,0.002056299,0.0002904999,0.01423257,0.000003443217,0.000005506431,0.00002049594,0.0001233455,0.1392083],"study_design_scores_gemma":[0.2127542,0.009749332,0.7738165,0.0008172627,0.000283379,0.0002613617,0.002118481,0.000003954822,0.00002437781,0.00005678998,0.00004179062,0.00007259563],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975587,0.0009243514,0.000005910767,0.0005365451,0.0001660279,0.0006403292,0.00007172035,0.000003598559,0.00009280696],"genre_scores_gemma":[0.9982163,0.001640539,0.00008398874,0.0000163851,0.000009977902,0.000003945904,0.000007956763,0.00001325192,0.000007684666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1391357,"threshold_uncertainty_score":0.4004906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01458484954283755,"score_gpt":0.2830322336540225,"score_spread":0.268447384111185,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}